Anterix officer plans $2.16M stock sale in 2026

Anterix Inc. (ATEX) received a notice that officer Christopher Guttman-McCabe plans to sell 23,439 shares of common stock, with an aggregate market value of $2,164,837.76, on or about 08/25/2026 under Rule 144 following a stock option exercise.

Rhea-AI Filing Summary

Anterix Inc. (ATEX) received a notice that officer Christopher Guttman-McCabe plans to sell 23,439 shares of common stock, with an aggregate market value of $2,164,837.76, on or about 08/25/2026 under Rule 144 following a stock option exercise. Common shares outstanding are reported as 19,609,786. In the prior three months, Guttman-McCabe reported sales of 122,852 shares of common stock for $10,042,745.59.

Key Figures

Shares to be sold: 23,439 shares Aggregate market value of planned sale: $2,164,837.76 Common shares outstanding: 19,609,786 shares +3 more

6 metrics

Shares to be sold 23,439 shares Common stock planned to be sold by Christopher Guttman-McCabe under Rule 144

Aggregate market value of planned sale $2,164,837.76 Value of 23,439 Anterix Inc. common shares to be sold

Common shares outstanding 19,609,786 shares Reported common shares outstanding for Anterix Inc.

Shares sold in past 3 months 122,852 shares Common shares sold by Christopher Guttman-McCabe on 06/15/2026

Aggregate value of past 3 months’ sales $10,042,745.59 Value of 122,852 common shares sold on 06/15/2026

Approximate date of planned sale 08/25/2026 Planned sale date for 23,439 shares under Rule 144

Key Terms

Rule 144, stock option exercise, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"Common | 08/25/2026 | Stock Option Exercise | Issuer |"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 23439 | 2164837.76 |"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider sale is disclosed for Anterix Inc. (ATEX) in this Form 144?

The filing reports that Christopher Guttman-McCabe plans to sell 23,439 shares of Anterix Inc. common stock, with an aggregate market value of $2,164,837.76, on or about 08/25/2026 under Rule 144 after a stock option exercise.

How many Anterix Inc. (ATEX) shares has the insider sold in the past three months?

Over the past three months, 122,852 shares of Anterix Inc. common stock were sold by Christopher Guttman-McCabe, for an aggregate sale value of $10,042,745.59, according to the Form 144 disclosure.

What is the reported market value of the planned Anterix Inc. (ATEX) share sale?

The planned sale by Christopher Guttman-McCabe covers 23,439 shares of Anterix Inc. common stock with an aggregate market value of $2,164,837.76, as stated in the Rule 144 notice.

How many Anterix Inc. (ATEX) shares are reported outstanding in this filing?

The Form 144 reports that Anterix Inc. has 19,609,786 common shares outstanding in connection with the insider’s planned Rule 144 sale.

What is the source of the Anterix Inc. (ATEX) shares to be sold under Rule 144?

The shares to be sold, totaling 23,439, are reported as arising from a stock option exercise by the issuer, with the planned sale date of 08/25/2026 and settlement in cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 04:25 PM EDT Accepted by SEC EDGAR 08/25/2026 - 04:25 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001828490
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ANTERIX INC.
SEC File Number	001-36827
Address of Issuer	3 Garret Mountain Plaza Suite 401 Woodland Park NEW JERSEY 07424
Phone	(973) 771-0300
Name of Person for Whose Account the Securities are To Be Sold	CHRISTOPHER GUTTMAN-MCCABE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	23439	2164837.76	19609786	08/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/25/2026	Stock Option Exercise	Issuer			23439	08/25/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CHRISTOPHER GUTTMAN-MCCABE 3 Garret Mountain Plaza Suite 401 Woodland Park NJ 07424	Common	06/15/2026	122852	10042745.59

144: Remarks and Signature

Remarks
Date of Notice	08/25/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Christopher Edward Guttman-McCabe
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)